The retention rates of IFX, ADA and ETN were 67%, 59% and 56% after 3 years; 62%, 42% and 47% after 5 years; 55%, 42% and 24% after 8 years; 53%, 42% and 12% after 10 years, respectively. In multivariate analyses, the predictive factors for retention were: low BASDAI score (hazard ratio 
Nevertheless, these RCTs were of short duration and included a selected population that differed from patients treated in daily practice. Biotherapy registries have thus been established in many countries in order to better understand long-term clinical efficacy and safety. However, these registries more often address rheumatoid arthritis than axSpA. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] While retention rates for anti-TNFs have been investigated using several patient registries, their follow-up duration did not typically exceed 8 years. 4, 5 Young age, male gender and presence of inflammatory syndrome appeared predictive of retention in most,
ALthough not all cases. 4, 7, 11, 12, 19 Other debated factors include the anti-TNF type prescribed, presence of other arthritis forms, and using conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in combination with anti-TNF therapy. 10, 11, 14, 16 In the event of treatment failure with a single anti-TNF, certain registries have assessed the efficacy of a second anti-TNF, ALthough with little data available on long-term retention. 6, 9, 11, 17 Only little data are also available on the retention of and response to anti-TNFs in reallife settings, in patients with non-radiographic axSpA (nr-axSpA). 18, 20 In France, as there is no specific anti-TNF registry, we have 
| MATERIALS AND METHODS
The between-group differences pertained to extra-articular manifestations that were more common in the IFX and ADA groups as compared to ETN; BASFI score that was lower among ADA-treated patients; acute phase reactants that were more severe in IFX-treated patients, and number of disease-modifying therapies used in combination with IFX (Table 1) . Patients on disease-modifying therapy more often presented with arthritis (53% vs 32%; P = 0.003), psoriasis (19% vs 182%; P = 0.17) or enterocolopathy (19% vs 7%; P = 0.007).
| BASDAI 50 response
Response at M6 was assessed in 178 patients, with the results detailed in There was no difference found between retention rates for ETN and those of both monoclonal antibodies combined (P = 0.13).
Treatment retention was superior when the therapy was initiated Patients who smoked were more likely to discontinue treatment, although the difference did not reach statistical significance (P = 0.08) ( Table 2 ).
In the multivariate analyses, the predictive factors for retention 
| Discontinuation due to either adverse effects or inefficacy
Overall, 23 (9.23%) patients discontinued their anti-TNF therapy due to adverse effects, with similar results obtained among the three anti-TNF groups (Table S2 and Figure S1 ). No predictive factors for drug discontinuation were identified.
When considering drug discontinuation due to inefficacy, the 1 year was 78%, 72% at 2 years, 62% at 3 years, 52% at 5 years and 38% at 10 years. Median retention duration was 69.7 months.
| DISCUSSION
The retention duration of the anti-TNF treatment over the study's early years was consistent with the data from several international registries. To illustrate, according to Czech registry ATTRA, retention was 84% at 1 year, 76% at 2 years and 72% at 3 years. 4 These figures were lower in the DANBIO registry, with a median drug retention of 4.3 years, with retention rates of 74% and 63% at 1 and 2 years, respectively. 4, 5 In our study, retention rates were higher SpA and undifferentiated SpA cases. 5, 16, 17 In our study, the patients exhibiting extra-spinal symptoms underwent disease-modifying therapy, and the fact that their condition was better managed possibly accounted for their higher treatment retention rates.
Treatment discontinuation was more commonly caused by the treatment's inefficacy than adverse effects (9.23%), with reasons for discontinuation varying depending on the registry considered. In our study, as in the Danish, 5, 11 Italian, and Spanish registries, 5,11,17 the most common cause for treatment discontinuation proved to be inefficacy. The discontinuation rate for inefficacy and adverse effects was the same in the Swedish and Brazilian registries, whereas the T A B L E 2 Predictive factors for first anti-tumor necrosis factor (TNF) treatment discontinuation Czech registry recorded adverse effects as the most common cause of drug discontinuation. 4, 14, 15 Although we found our discontinuation rate due to undesirable effects to be relatively low compared to that of other registries, it was nevertheless close to that observed in the NOR-DMARD registry (8.5%). 8 Retention of the initial anti-TNF treatment was superior in patients exhibiting severe biological inflammatory syndromes, consistent with the data of the Danish and Czech registries, as well as an
Italian multicenter study, yet contrasting with the findings of a Swedish and French study. 4, 9, 11, 12, 18 According to the Danish registry, low BASDAI score proved to be a predictive factor for retention in univariate analysis, yet not in the multivariate analyses. 5 Retention was not as good in patients with non-radiographic SpA compared to those with radiographic SpA, which proved to be contrary to the Lille study's findings. 18 Other results were revealed to differ from those reported in certain registries. These include male gender as a predictive factor for retention in the ATTRA, DANBIO and SSATG registries. 4, 5, 14 SpA disease duration, and smoking. 19 In total, 61 of our patients switched to another anti-TNF therapy, and there was no difference in the median retention duration observed when comparing the three anti- The predictive factors for good response to an initial anti-TNF therapy were young age at the start of treatment, being a non-smoker, and exhibiting high CRP levels. Our data thus agree those of the DANBIO registry with regard to age and inflammatory syndromes. 5 High CRP levels were also a predictive response factor in the BSRBR registry, 22 whereas smoking was predictive of non-response, as highlighted in the DANBIO registry. 19 Conflicting data were reported concerning the response of radiographic vs non-radiographic SpA patients. Data from the Swiss registry SCQM revealed lower response in non-radiographic SpA patients, although the difference was less significant for patients exhibiting high CRP levels. 23 In the Lille study, no difference was observed between radiographic and non-radiographic SpA cases. 18 Our study found non-radiographic SpA to be a predictive factor of non-response in univariate analysis, yet not in the multivariate analyses.
Our study's principal limitation was its observational nature and retrospective design. In the absence of randomization, patients with different discontinuation risks may have been channeled to a specific treatment, thereby causing selection bias and potentially affecting our analysis. Furthermore, the patient sample size was perhaps too small, especially for subgroup analyses. Our study's strength lies in the fact that it presents the experiences reported by the same team with 10 years of hindsight, which proves to be an unprecedented achievement.
The retention rates of anti-TNFs in axSpA patients proved high, with retention superior in those on IFX than those on ETN. The presence of inflammatory syndrome, moderately increased BASDAI score, and the combined use of csDMARDs were associated with even better retention.
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